Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Progesterone Resistance 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

Paclitaxel 79Carboplatin 66pembrolizumab 61Bevacizumab 56Cisplatin 48Specimen Handling 29Drug Therapy 26Blood Specimen Collection 24Cyclophosphamide 20olaparib 19Taxes 17Magnetic Resonance Spectroscopy 16Letrozole 16Gemcitabine 16Biopsy 16liposomal doxorubicin 15niraparib 14fludarabine 14Brachytherapy 14Radiotherapy 13abemaciclib 12Topotecan 11Nivolumab 11Injections 11Doxorubicin 11lenvatinib 10Fluorouracil 10atezolizumab 9Surveys and Questionnaires 9Standard of Care 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cyproterone acetate, ethinyl estradiol drug combination × Gynecologic × Clear all
NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Fudan University

Phase 2/3 Recruiting
80 enrolled
Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡